MARKET

BBI

BBI

Brickell Biotech Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.8885
+0.0444
+5.26%
Opening 11:12 04/19 EDT
OPEN
0.8500
PREV CLOSE
0.8441
HIGH
0.9096
LOW
0.8500
VOLUME
1.06M
TURNOVER
--
52 WEEK HIGH
2.610
52 WEEK LOW
0.4660
MARKET CAP
59.47M
P/E (TTM)
-0.6641
1D
5D
1M
3M
1Y
5Y
Brickell Biotech Announces Presentation of US Phase 3 Open-Label Long-Term Safety Study Results for Sofpironium Bromide Gel at the Late-Breaking Research Program during American Academy of Dermatology's 2021 VMX
Brickell Biotech, Inc. ("Brickell" or the "Company") (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that ...
GlobeNewswire · 3d ago
BRIEF-Brickell Biotech Announces Publication Of HDSM-AX Patient Reported Outcome Scale Validation Results In The Journal Of Drugs In Dermatology
reuters.com · 4d ago
Brickell Biotech Highlights Publication Of Its HDSM-Ax Patient Reported Outcome Scale Validation Results In Journal Of Drugs In Dermatology
Brickell Biotech, Inc. ("Brickell" or the "Company") (NASDAQ:BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the
Benzinga · 4d ago
Brickell Biotech Announces Publication of its HDSM-Ax Patient Reported Outcome Scale Validation Results in the Journal of Drugs in Dermatology
Brickell Biotech, Inc. (“Brickell” or the “Company”) (NASDAQ:BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the
Benzinga · 4d ago
Brickell Biotech (BBI) Receives a Buy from Oppenheimer
In a report released today, Leland Gershell from Oppenheimer maintained a Buy rating on Brickell Biotech (BBI), with a price target of $5.00. The
SmarterAnalyst · 03/29 12:32
Neos Therapeutics, Aytu BioScience leads healthcare gainers; Translate Bio, ContraFect among major losers
Gainers: Neos Therapeutics (NEOS) +17%,Aytu BioScience (AYTU) +14%, Vericel (VCEL) +14%, Brickell Biotech (BBI) +14%, Infinity Pharmaceuticals INFI +13%.Losers: Translate Bio TBIO -32%, ContraFect CFRX -13%, Lipocine (LPCN) -11%, Olema Pharmaceuticals (OLM...
Seekingalpha · 03/18 15:02
Thinking about buying stock in Can Fite Biopharma, Aytu Bioscience, Hall of Fame Resort & Entertainment, Brickell Biotech, or Infinity Pharmaceuticals?
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CANF, AYTU, HOFV, BBI, and INFI.
PR Newswire - PRF · 03/18 12:30
HEXO, CSIQ, LAZR and SIG among premarket gainers
BioHiTech Global (BHTG) +44% on receiving $2M in Digester orders.Upstart Holdings (UPST) +39% on Q4 results.Neos Therapeutics (NEOS) +30%.Seneca Biopharma (SNCA) +26%.Evolving Systems (EVOL) +24% on Q4 results.Can-Fite BioPharma (CANF) +17% on announcing n...
Seekingalpha · 03/18 12:29
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BBI. Analyze the recent business situations of Brickell Biotech Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BBI stock price target is 5.50 with a high estimate of 6.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 49
Institutional Holdings: 6.20M
% Owned: 9.27%
Shares Outstanding: 66.93M
TypeInstitutionsShares
Increased
6
1.14M
New
11
2.09M
Decreased
2
30.24K
Sold Out
3
737.68K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.89%
Pharmaceuticals & Medical Research
-0.43%
Key Executives
Chairman/Co-Founder/Director
Reginald Hardy
Chief Executive Officer/Director
Robert Brown
Co-Founder/Chief Operating Officer/Secretary
Andrew Sklawer
Chief Financial Officer
R. Carruthers
Chief Financial Officer
Albert Marchio
Chief Accounting Officer/Controller
Jose Breton
Chief Compliance Officer/General Counsel/Secretary
David McAvoy
Other
Deepak Chadha
Other
Adam Levy
Director
Gary Lyons
Director
Vijay Samant
Director
Dennison Veru
No Data
About BBI
Brickell Biotech, Inc., formerly Vical Incorporated, is a clinical-stage pharmaceutical company that focuses on the development of therapeutics for the treatment of skin diseases. The Company’s pipeline consists of molecular entities targeting the treatment of the indications, such as hyperhidrosis, cutaneous T-cell lymphoma, allergic contact dermatitis, psoriasis and androgenic alopecia. The Company’s product candidates include BBI-3000, BBI-6000 and Sofpironium Bromide. Sofpironium Bromide is a topical soft anticholinergic for axillary hyperhidrosis. BBI-3000 is an oral rexinoid for cutaneous T-cell lymphoma. BBI-6000 is a retinoic acid-related orphan nuclear receptor gamma antagonist, which is develops for psoriasis.

Webull offers kinds of Brickell Biotech Inc stock information, including NASDAQ:BBI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BBI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BBI stock methods without spending real money on the virtual paper trading platform.